Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumacaftor/ivacaftor crossover study in cystic fibrosis with A455E-CFTR mutation
NL-OMON46161Phase 2Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lumacaftor and ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute change from baseline in percent predicted forced expiratory volume in 1 second. Started Jan 2017; status: active, not recruiting.
02
Drugs
lumacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON46161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46161.